Spravato x Motor City Medical Group
SPRAVATO® offered at Motor City Medical Group is a prescription medicine, used along with an antidepressant taken by mouth to treat adults with treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions.
What is Spravato?

Spravato is the first FDA-approved nasal spray medication, taken with an oral antidepressant, for treatment-resistant depression in adults. If you have tried two or more antidepressants without sufficient relief, Spravato might be for you. Follow the link at the bottom of this page to set a consultation with Motor City Medical Group in order to learn more about Spravato treatment.

SPRAVATO® (esketamine) CIII nasal spray is a nonselective, noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor – an ionotropic glutamate receptor. It is a first-of-its kind medicine approved by the FDA in two major depressive disorder (MDD) subpopulations with high unmet need.


SPRAVATO® is available only through a restricted distribution program called the SPRAVATO® REMS. A REMS program is in place to ensure the safety of all patients who are treated with SPRAVATO®. Motor City Medical Group operates underneath the REMS program for service implementation at our offices.

The goals of the REMS are to mitigate the risks of serious adverse outcomes resulting from sedation and dissociation caused by SPRAVATO® administration, and abuse and misuse of SPRAVATO®, by: ensuring SPRAVATO® is only dispensed and administered to patients in medically supervised healthcare settings that monitor these patients, ensuring pharmacies and healthcare settings that dispense SPRAVATO® are REMS certified, ensuring patients are informed about serious adverse outcomes from dissociation and sedation and the need for monitoring, and enrolling all patients who receive treatment in an outpatient healthcare setting in a REMS registry to further characterize the risks and support safe use.

NOTE: While SPRAVATO® and ketamine are chemically related, SPRAVATO® is not the same as IV ketamine. Only SPRAVATO® has undergone extensive controlled clinical trials that informed the FDA approval of the medicine for use in adults with treatment resistant depression and to treat depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.

First Visit

Watch this video in order to get best prepared for your first Spravato visit

Patient Stories


Watch this video in order to learn more about a personal experience with Spravato

Ready for change

Set up Your First Consultation

Click the link below to begin your journey with Spravato

contact us
Today is the day that your journey to overall wellness can begin. Click below in order to start your intake form.
Ready to experience change?
Start Now